Skip to main content
Top
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Case report

An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: A case report

Authors: Sachin Gupta, Amit Jain, Tina V Fanning, Daniel R Couriel, Carlos A Jimenez, Georgie A Eapen

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Hematopoietic stem cell transplantation is being increasingly used in cancer therapy. Diffuse alveolar hemorrhage, an early complication of stem cell transplant, results from bacterial, viral and fungal infections, coagulopathy, and engraftment syndrome, or can be idiopathic. Diffuse alveolar hemorrhage associated with Strongyloides stercoralis hyperinfection in stem cell transplant patients has been rarely reported.

Case presentation

We describe an unusual cause of alveolar hemorrhage post hematopoietic stem cell transplant due to Strongyloides hyperinfection. Therapy with parenteral ivermectin and thiabendazole was initiated but the patient deteriorated and died of respiratory failure and septic shock.

Conclusion

Strongyloides stercoralis hyperinfection is an unusual cause of alveolar hemorrhage early after hematopoietic stem cell transplant with very high mortality.
Appendix
Available only for authorised users
Literature
1.
go back to reference Safdar A, Malathum K, Rodriguez SJ, Husni R, Rolston KV: Strongyloidiasis in patients at a comprehensive cancer center in the United States. Cancer. 2004, 100: 1531-1536. 10.1002/cncr.20120.CrossRefPubMed Safdar A, Malathum K, Rodriguez SJ, Husni R, Rolston KV: Strongyloidiasis in patients at a comprehensive cancer center in the United States. Cancer. 2004, 100: 1531-1536. 10.1002/cncr.20120.CrossRefPubMed
2.
go back to reference Genta RM: Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis. 1989, 11: 755-767.CrossRefPubMed Genta RM: Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis. 1989, 11: 755-767.CrossRefPubMed
3.
go back to reference Igra-Siegman Y, Kapila R, Sen P, Kaminski ZC, Louria DB: Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis. 1981, 3: 397-407.CrossRefPubMed Igra-Siegman Y, Kapila R, Sen P, Kaminski ZC, Louria DB: Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis. 1981, 3: 397-407.CrossRefPubMed
4.
go back to reference Kerlin RL, Nolan TJ, Schad GA: Strongyloides stercoralis: histopathology of uncomplicated and hyperinfective strongyloidiasis in the Mongolian gerbil, a rodent model for human strongyloidiasis [corrected]. Int J Parasitol. 1995, 25: 411-420. 10.1016/0020-7519(94)00154-G.CrossRefPubMed Kerlin RL, Nolan TJ, Schad GA: Strongyloides stercoralis: histopathology of uncomplicated and hyperinfective strongyloidiasis in the Mongolian gerbil, a rodent model for human strongyloidiasis [corrected]. Int J Parasitol. 1995, 25: 411-420. 10.1016/0020-7519(94)00154-G.CrossRefPubMed
5.
go back to reference Lim S, Katz K, Krajden S, Fuksa M, Keystone JS, Kain KC: Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ. 2004, 171: 479-484.CrossRefPubMedPubMedCentral Lim S, Katz K, Krajden S, Fuksa M, Keystone JS, Kain KC: Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ. 2004, 171: 479-484.CrossRefPubMedPubMedCentral
6.
go back to reference Orlent H, Crawley C, Cwynarski K, Dina R, Apperley J: Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003, 32: 115-117. 10.1038/sj.bmt.1704104.CrossRefPubMed Orlent H, Crawley C, Cwynarski K, Dina R, Apperley J: Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003, 32: 115-117. 10.1038/sj.bmt.1704104.CrossRefPubMed
7.
go back to reference Concha R, Harrington W, Rogers AI: Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol. 2005, 39: 203-211. 10.1097/01.mcg.0000152779.68900.33.CrossRefPubMed Concha R, Harrington W, Rogers AI: Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol. 2005, 39: 203-211. 10.1097/01.mcg.0000152779.68900.33.CrossRefPubMed
8.
go back to reference Genta RM: Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis. Am J Clin Pathol. 1988, 89: 391-394.CrossRefPubMed Genta RM: Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis. Am J Clin Pathol. 1988, 89: 391-394.CrossRefPubMed
9.
go back to reference Datry A, Hilmarsdottir I, Mayorga-Sagastume R, Lyagoubi M, Gaxotte P, Biligui S, Chodakewitz J, Neu D, Danis M, Gentilini M: Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg. 1994, 88: 344-345. 10.1016/0035-9203(94)90110-4.CrossRefPubMed Datry A, Hilmarsdottir I, Mayorga-Sagastume R, Lyagoubi M, Gaxotte P, Biligui S, Chodakewitz J, Neu D, Danis M, Gentilini M: Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg. 1994, 88: 344-345. 10.1016/0035-9203(94)90110-4.CrossRefPubMed
Metadata
Title
An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: A case report
Authors
Sachin Gupta
Amit Jain
Tina V Fanning
Daniel R Couriel
Carlos A Jimenez
Georgie A Eapen
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-87

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine